- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.STAT · 50m ago↗ source
- A trend that isn’t fading, ultra-processed baby foodsAn FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning RoundsSTAT · 1h ago↗ source
- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.STAT · 1h ago